You can narrow down the results using the filters
-
A pharmacokinetic phase I study to assess the bioavailability and pharmacokinetics of Fentanyl from a metered dose transdermal system (MDTS) in pain
Expand description -
A Phase I Study to Determine the Pharmacokinetics of Nestorone Delivered with the Metered Dose Transdermal System (MDTS) in Postmenopausal Women, to be used in contraception
Expand description -
A phase I pharmacokinetic study to compare the steady-state pharmacokinetics of testosterone following application of a Testosterone Metered-Dose Transdermal Spray (MDTS) to the forearm or abdomen in healthy postmenopausal women with low libido and low serum testosterone
Expand description -
A phase I study to compare the steady-state pharmacokinetics of estradiol following application to the abdomen of an Estradiol Metered-Dose Transdermal Spray (MDTS) and Estraderm 50 patches in healthy postmenopausal women, as hormone replacement therapy.
Expand description -
A Pharmacokinetic Phase I Study to Assess the Effect of Different Application Sites and Formulations, on the Relative Bioavailability and Pharmacokinetics of Estradiol in postmenopausal women from a Metered Dose Transdermal System (MDTS) as hormone replacement therapy.
Expand description -
A Study to Determine the Linearity of the Pharmacokinetics and the Effect of Washing the Application Site on the Bioavailability of Estradiol from an Estradiol MDTS as hormone replacement therapy in post-menopausal women
Expand description -
A pharmacokinetic phase I study to assess the effect of different application sites on the pharmacokinetics of testosterone from a Testosterone Metered Dose (MD) Lotion in hypogonadism.
Expand description -
A randomised, two-way crossover study to compare the pharmacokinetics of testosterone following application of a Testosterone Metered Dose (MD) lotion or AndroGel in men with low serum testosterone
Expand description -
Switching to aripiprazole from other second-generation antipsychotics.
Expand descriptionThe aims of this project are to: - Monitor the benefits and risks of slowly reducing the dosage of previous antipsychotic medicine, while taking aripiprazole. We expect that either of the reductions, unlike sudden discontinuation, will prevent a relapse of your illness. - Assess the side effects and changes in mental state weekly during tapering, and the remainder of the 12 weeks study. We expect that the slower of the two reductions will be accompanied by fewer side effects. - Assess weight, and other complications of obesity, over a period of 12 weeks. We expect weight gain to cease, or even reverse. - Assess psychological and other brain functions over 12 weeks. We expect that thinking, remembering, coordination etc., will improve. - Assess sexual interest and performance over three months. We expect these to improve for patients previously taking medicines known to have these side effects.
-
Open label longitudinal study of Botox and chronic pelvic pain 03/102
Expand description: To assess response to Botox injections of the pelvic floor in women with documented pelvic floor muscle spasm with regards to pain, quality of life and anxiety state and to determine an efficacy curve and dosage intervals for repeat injections.